Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders
Bright Minds Biosciences Inc. shares climbed on Wednesday after Piper Sandler boosted its price target on the company. DRUG closed at $82.78 on the Nasdaq, jumping 11.1% from Tuesday’s $74.54 finish. The new target puts the stock in focus for Thursday’s U.S. trading. That’s relevant since U.S. markets were still closed at the dateline. Regular hours at Nasdaq are 9:30 a.m. to 4:00 p.m. Eastern, with pre-market hours ahead of that. So Wednesday’s close was the last official mark.